

Fig. 14





Fig. 18





4/23




Fig. 26




Fig. 34




Fig.3B




Fig.4A

8/23





Fig. 46

WO 2005/017523 PCT/GB2004/003512

9/23



10/23




Fig.5E

WO 2005/017523 PCT/GB2004/003512

11/23




Fig. 64




Fig. 6B




Fig. 7.4




Fig. 7E




Fig. 7C




Fig.84




Fig.8B




Fig.80




Fig. 94 15




Fig.9B





Fig.9C

Figure 5. Determination of ApoC-III level in 14 haemorrhagic and 13 ischaemic stroke plasma samples compared to 30 negative controls using Daiichi tests (Cobas Mira plus automate)



| Specificity | 71.42 % | % 09 | • |
|------------------|---------|-----------|-----------|
| Sensitivity S | 92.3 % | 92.3 % | |
| p (student test) | 0.0342 | 0.025 | 0.4682 |
| | H sv I | I vs Ctrl | H vs Ctrl |

WO 2005/017523 PCT/GB2004/003512

. 23/23

Fig. 11

